Impact of Haemophilus influenzae b (Hib) vaccination on meningitis in Central Brazil

To assess the impact of the Haemophilus influenzae b (Hib) conjugate vaccine in reducing the incidence of meningitis among children under five years old. A 'before-after' design was used to compare Hib meningitis incidence rates in the pre-vaccine (July 1995 - June 1999) and post-vaccine (...

Full description

Saved in:
Bibliographic Details
Published in:Revista de saúde pública 2004-10, Vol.38 (5), p.664-670
Main Authors: Simões, Luciana Leite Pineli, Andrade, Ana Lúcia S S, Laval, Cristina A, Oliveira, Renato M, Silva, Simmone A, Martelli, Celina M T, Alves, Sueli L de A, Almeida, Robmary M, Andrade, João G
Format: Article
Language:Portuguese
Subjects:
Brazil - epidemiology
Child, Preschool
Female
Haemophilus influenzae type b - immunology
Haemophilus Vaccines - administration & dosage
Humans
Incidence
Infant
Male
Meningitis, Haemophilus - epidemiology
Meningitis, Haemophilus - prevention & control
Tetanus Toxoid - administration & dosage
Vaccines, Conjugate - administration & dosage
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To assess the impact of the Haemophilus influenzae b (Hib) conjugate vaccine in reducing the incidence of meningitis among children under five years old. A 'before-after' design was used to compare Hib meningitis incidence rates in the pre-vaccine (July 1995 - June 1999) and post-vaccine (July 1999 - June 2001) periods in the state of Goias, central Brazil. Bacterial meningitis case definition was based on World Health Organization criteria. Incidence rates of S. pneumoniae and N. meningitidis were used for comparison purposes. Chi-squared and Student's t tests were used for statistical analysis. P-values below 0.05 were considered as statistically significant. 979 children with acute bacterial meningitis were detected throughout the entire period. The incidence rate of Hib meningitis decreased from 10.8 (x10(5)) in the pre-vaccine period to 2.3 (x10(5)) in the 2nd year post vaccination, leading to a risk reduction of 78%, targeted to the 7-23 months age group (p
ISSN:0034-8910